Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Green Cross Corporation has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 3 distinct examiners and 3 distinct art units. This distribution of 3 pending office actions among 3 distinct examiners and 3 distinct art units means that each pending matter is being reviewed in a unique environment within the USPTO. There is no overlap in the personnel or the specialized groups reviewing these 3 cases.
The busiest examiner, HAGHIGHATIAN, MINA, is responsible for 1 pending office action. This distribution means that each of the 3 pending office actions is being evaluated by a different examiner in a different specialized art unit. Practitioners cannot rely on a single examiner's patterns to predict the outcome of the entire portfolio. Instead, they must prepare for 3 distinct sets of examiner preferences and 3 different art unit standards across the 3 pending office actions currently under review, ensuring a highly customized approach for the Biotechnology & Pharmaceuticals field.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HAGHIGHATIAN, MINA | 1 | 46.0% | +39.4% |
| DAHLIN, HEATHER RAQUEL | 1 | 42.2% | +47.1% |
| XU, QING | 1 | 50.9% | +55.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18559466 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST GLUCOSYLCERAMIDE SYNTHASE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESSES FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | DAHLIN, HEATHER RAQUEL | 2d overdue |
| 18864068 | NOVEL LIQUID FORMULATION FOR PLASMA PROTEIN | HAGHIGHATIAN, MINA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18559466 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST GLUCOSYLCERAMIDE SYNTHASE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESSES FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | DAHLIN, HEATHER RAQUEL | 2d overdue |
| 18864068 | NOVEL LIQUID FORMULATION FOR PLASMA PROTEIN | HAGHIGHATIAN, MINA | — |
| 17059875 | METHOD AND COMPOSITION FOR TREATING HUNTER SYNDROME THROUGH CEREBRAL LATERAL VENTRICLE ADMINISTRATION | XU, QING | — |
| Art Unit | Apps |
|---|---|
| 1616 | 1 |
| 1629 | 1 |
| 1656 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18864068 | NOVEL LIQUID FORMULATION FOR PLASMA PROTEIN | HAGHIGHATIAN, MINA | 1616 | §102§103§112 | Non-Final OA | — | Pending | Nov 08, 2024 |
| 18559466 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST GLUCOSYLCERAMIDE SYNTHASE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESSES FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | DAHLIN, HEATHER RAQUEL | 1629 | §102§112 | Final Rejection | 2d overdue | Pending | Nov 07, 2023 |
| 17059875 | METHOD AND COMPOSITION FOR TREATING HUNTER SYNDROME THROUGH CEREBRAL LATERAL VENTRICLE ADMINISTRATION | XU, QING | 1656 | §103Other | Final Rejection | — | Pending | Nov 30, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGreen Cross Corporation has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Mina Haghighatian has the most, with 1 of Green Cross Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
